Company news
Alvotech (NASDAQ:ALVO) news
Every Alvotech press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Alvotech to present at upcoming investor conferences in September
August 27, 2026
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizu...
August 21, 2026
Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update
August 19, 2026
Alvotech announces successful closure of FDA inspection of manufacturing facility
July 29, 2026
Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggre...
June 18, 2026
Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement
June 15, 2026
Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
June 15, 2026
Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
June 8, 2026
Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, an...
June 4, 2026
Alvotech to present at upcoming investor conferences in June
June 2, 2026
Alvotech and Islandsbanki renew Market Making Agreement for ALVO Shares Trading on Nasdaq Iceland
June 1, 2026
Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility
May 11, 2026
Alvotech Q1 2026 Financial Results
May 6, 2026
Alvotech Announces a Change in its Executive Team
April 30, 2026
Alvotech to Report Financial Results for the First Quarter of 2026
April 24, 2026
Alvotech Files Annual Report with the SEC
March 30, 2026
Alvotech Publishes 2025 Annual Report
March 30, 2026
Alvotech files Annual Report with the SEC
March 30, 2026
Alvotech Q4 2025 and Full Year 2025 Financial Results
March 18, 2026
Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results
March 4, 2026
Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
February 5, 2026
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
February 2, 2026
Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg
January 29, 2026
Correction: Transactions of Managers and Closely Associated Persons
January 7, 2026
Alvotech announces planned CEO succession and leadership transition
January 6, 2026
Transactions of Managers and Closely Associated Persons
January 6, 2026
Alvotech Secures Term Loan Facility of USD 100 Million
December 31, 2025
Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma
December 22, 2025
Alvotech’s Financial Calendar for 2026
December 22, 2025
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
December 19, 2025
Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering
December 17, 2025
Alvotech Launches $100 Million Senior Unsecured Convertible Bond Offering to Continue Strong Investment in R&D, Support Manufacturing, Gl...
December 16, 2025
Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area
November 24, 2025
Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Sim...
November 20, 2025
Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update
November 12, 2025
UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)
November 10, 2025
UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)
November 10, 2025
Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA
November 6, 2025
Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update
November 4, 2025
Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05
November 2, 2025
Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05
November 2, 2025
Alvotech Announces Changes in Global Business Development and Commercial Operations Team
October 22, 2025
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency
October 6, 2025
Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application b...
October 6, 2025
European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz P...
September 22, 2025
European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®
September 22, 2025
Alvotech Announces Marketing Approval in Japan of Three New Biosimilars
September 19, 2025
Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York
September 4, 2025
Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
August 21, 2025
Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia
August 20, 2025